DMAC
DiaMedica Therapeutics Inc.
Key Financials
Net Income
$-32766000
↓ 34.0%
Operating Income
$-34397000
↓ 28.9%
Cash & Equivalents
$15.6M
↑ 417.3%
Total Assets
$61.4M
↑ 32.4%
Shareholders' Equity
$56.1M
↑ 37.8%
Operating Cash Flow
$-29062000.00
↓ 31.6%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 5/6/2026 | View on SEC |
| 8-K | 5/6/2026 | View on SEC |
| ARS | 4/1/2026 | View on SEC |
| DEFA14A | 4/1/2026 | View on SEC |
| DEF 14A | 4/1/2026 | View on SEC |
| 8-K | 3/31/2026 | View on SEC |
| 10-K | 3/30/2026 | View on SEC |
| SCHEDULE 13G/A | 2/17/2026 | View on SEC |
| SCHEDULE 13G/A | 2/17/2026 | View on SEC |
| SCHEDULE 13G/A | 2/6/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | DMAC |
| Company Name | DiaMedica Therapeutics Inc. |
| CIK | 1401040 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | Z4 |
| Phone | (763) 496-5454 |